Toshiba Medical, of Tustin, Calif., has provided physicians with imaging technology for fast, safe, and reliable evaluation of liver lesions with the premium Aplio i-series ultrasound platform. With the recent expansion of Liver Imaging Reporting and Data System (LI-RADS) to include contrast-enhanced ultrasound (CEUS) imaging for hepatocellular carcinoma (HCC) characterization, the Aplio i-series seeks to offer an ideal solution for confident diagnoses.

The Aplio i-series is a highly advanced and scalable ultrasound solution made up of the Aplio i700 and Aplio i800. Health systems, such as UC San Diego Health, are using the Aplio i-series’ imaging resolution and penetration, and comprehensive CEUS imaging and quantification package, to assess perfusion dynamics in the liver and help improve HCC surveillance results.

“The Aplio i-series offers the superb image quality clinicians need to make confident diagnosis and provide excellent patient care,” says Dan Skyba, director of the ultrasound business unit at Toshiba America Medical Systems Inc. “Combining a brand new system architecture with matrix transducer technology and a world-renowned CEUS imaging package, these premium systems offer best-in-class resolution, penetration, and dynamic contrast visualization.

Skyba adds, “The Aplio i-series facilitates small HCC diagnosis and surveillance, even in obese or difficult-to-image patients, while improving workflow and keeping patients safe and more comfortable. As the transition to a value-based healthcare system continues, the use of CEUS for characterization of focal liver lesions is an example of a cost-effective and high-value clinical solution.”